Nicotine patches, gums won’t help smokers quit long-term
Nicotine patches and nicotine gum — the popular mainstays of so-called “nicotine replacement therapy” — don’t help many smokers kick the habit and remain cigarette-free over the long haul, new research suggests. The study authors concluded that the findings raise “serious questions” about the effectiveness of nicotine replacement therapy as experienced by most smokers. This […]
Read More »Category : News
Boehringer’s Pradaxa Increases Risk of Heart Attack, Study Shows
Boehringer Ingelheim GmbH’s anti- coagulant Pradaxa increases a patient’s risk of heart attack or severe chest pain, according to a review of studies conducted on the drug. An analysis of seven clinical trials found that it was “significantly associated with a higher risk†of heart attacks and acute coronary syndrome, or ACS, a designation that […]
Read More »Category : News
CROs Blast New Clinical Trial Rules In India
Overseas clinical trials are a perennially controversial issue, but especially in India, where the population is regularly tapped by overseas drugmakers. At the same time, the Indian government is increasingly concerned about patients. Notably, India’s health ministry last year found that drugmakers running clinical trials had not compensated survivors of most volunteers who died during […]
Read More »Category : News
Senator warns FDA on danger of newest super painkillers now under review after NY shooting
Following fatal shootings in two New York pharmacy robberies, a U.S. senator is warning that a new batch of “super painkillers†now under review could force repeats of recent violent robberies that left six people dead. “It’s tremendously concerning that at the same time policymakers and law enforcement professionals are waging a war on the […]
Read More »Category : News
What Novartis Did Wrong At Its Consumer Plant
Last month, Novartis quietly suspended production at a plant in Lincoln, Nebraska, where various over-the-counter and animal health meds are made. The drugmaker called the move a voluntary step to improve compliance and strengthen standards (back story). However, when we asked about any regulatory actions that may have prompted its decision, the drugmaker would only […]
Read More »Category : News
Docs To Hospira: Restrict Med Used For Executions
The ongoing shortage of drugs used for prison executions has prompted more than two dozen prominent physicians from different countries to write to Hospira ceo Michael Ball, urging him to restrict the use of Pancuronium, which is one of three drugs that are used in a lethal injection cocktail administered by many states in the […]
Read More »Category : News
AstraZeneca leaks confidential information
There have been red faces at AstraZeneca after the company sent confidential information to analysts by mistake. It was forced into issuing a clarification about its financial prospects, saying that the information it inadvertently let out “does not represent the company’s view of expected financial performance for the full year 2011 or for future periodsâ€. […]
Read More »Category : News
Novartis Recalls OTC Meds Made At Troubled Plant
Less than a month after quietly shutting a plant that makes over-the-counter and animal health meds, Novartis has now recalled an unspecified number of OTC drugs – including Excedrin, No-Doz and Bufferin – due to complaints about incorrect or chipped tablets and broken gelcaps, as well as an FDA review that found inconsistent bottle packaging […]
Read More »Category : News
Parents sue Pfizer over birth defects allegedly caused by Zoloft
A group of parents who claim their children suffered severe birth defects because of Zoloft has filed a lawsuit against the drug’s manufacturer. Mary and David Saville, Terry and Todd Cochran, Anita Kinslow, Wendell Houchens, Erica Woodley and Antwynette Golliday joined a lawsuit filed Dec. 2 in St. Clair County Circuit Court against Pfizer Inc. […]
Read More »Category : News
Xoma shifts manufacturing to contractor, cuts 84 jobs
Xoma Corp. will cut 84 jobs — about one-third of its workforce — as the Berkeley-based drug developer shifts much of its manufacturing to a contractor. Xoma (NASDAQ: XOMA), which officially took “interim†off CEO John Varian’s title, said Thursday that it will eliminate 50 jobs immediately and cut the other 34 jobs by the […]
Read More »Category : News
